These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

116 related articles for article (PubMed ID: 38898592)

  • 1. Safety, pharmacokinetics, pharmacodynamics, and antitumor activity of SAR439459, a TGFβ inhibitor, as monotherapy and in combination with cemiplimab in patients with advanced solid tumors: Findings from a phase 1/1b study.
    Baranda JC; Robbrecht D; Sullivan R; Doger B; Santoro A; Barve M; Grob JJ; Bechter O; Vieito M; de Miguel MJ; Schadendorf D; Johnson M; Pouzin C; Cantalloube C; Wang R; Lee J; Chen X; Demers B; Amrate A; Abbadessa G; Hodi FS
    Clin Transl Sci; 2024 Jun; 17(6):e13854. PubMed ID: 38898592
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biomarker and pharmacodynamic activity of the transforming growth factor-beta (TGFβ) inhibitor SAR439459 as monotherapy and in combination with cemiplimab in a phase I clinical study in patients with advanced solid tumors.
    Robbrecht D; Grob JJ; Bechter O; Simonelli M; Doger B; Borbath I; Butler MO; Cheng T; Romano PM; Pons-Tostivint E; Di Nicola M; Curigliano G; Ryu MH; Rodriguez-Vida A; Schadendorf D; Garralda E; Abbadessa G; Demers B; Amrate A; Wang H; Lee JS; Pomponio R; Wang R
    Clin Transl Sci; 2024 Feb; 17(2):e13736. PubMed ID: 38362837
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Dual CTLA-4 and PD-1 checkpoint blockade using CS1002 and CS1003 (nofazinlimab) in patients with advanced solid tumors: A first-in-human, dose-escalation, and dose-expansion study.
    Bishnoi S; Kotasek D; Aghmesheh M; Yau T; Cosman R; Prawira A; Moore M; Chan SL; Mant A; Eek R; Zielinski R; Su R; Pan Z; Ma Y; Li F; Li P; Tse AN
    Cancer; 2024 Jun; 130(11):1991-2002. PubMed ID: 38404184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Phase 1b study of galunisertib and ramucirumab in patients with advanced hepatocellular carcinoma.
    Harding JJ; Do RK; Yaqubie A; Cleverly A; Zhao Y; Gueorguieva I; Lahn M; Benhadji KA; Kelley RK; Abou-Alfa GK
    Cancer Med; 2021 May; 10(9):3059-3067. PubMed ID: 33811482
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase I Study of MEDI3617, a Selective Angiopoietin-2 Inhibitor Alone and Combined with Carboplatin/Paclitaxel, Paclitaxel, or Bevacizumab for Advanced Solid Tumors.
    Hyman DM; Rizvi N; Natale R; Armstrong DK; Birrer M; Recht L; Dotan E; Makker V; Kaley T; Kuruvilla D; Gribbin M; McDevitt J; Lai DW; Dar M
    Clin Cancer Res; 2018 Jun; 24(12):2749-2757. PubMed ID: 29559563
    [No Abstract]   [Full Text] [Related]  

  • 6. Evorpacept alone and in combination with pembrolizumab or trastuzumab in patients with advanced solid tumours (ASPEN-01): a first-in-human, open-label, multicentre, phase 1 dose-escalation and dose-expansion study.
    Lakhani NJ; Chow LQM; Gainor JF; LoRusso P; Lee KW; Chung HC; Lee J; Bang YJ; Hodi FS; Kim WS; Santana-Davila R; Fanning P; Squifflet P; Jin F; Kuo TC; Wan HI; Pons J; Randolph SS; Messersmith WA
    Lancet Oncol; 2021 Dec; 22(12):1740-1751. PubMed ID: 34793719
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A first-in-human, open-label, dose-escalation and dose-expansion phase I study to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics, and antitumor activity of QL1604, a humanized anti-PD-1 mAb, in patients with advanced or metastatic solid tumors.
    Huang Z; Xu Y; Hong W; Gong L; Chen K; Qin J; Xie F; Wang F; Tian X; Meng X; Feng W; Li L; Zhang B; Kang X; Fan Y
    Front Immunol; 2023; 14():1258573. PubMed ID: 37936687
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Phase I study of emactuzumab single agent or in combination with paclitaxel in patients with advanced/metastatic solid tumors reveals depletion of immunosuppressive M2-like macrophages.
    Gomez-Roca CA; Italiano A; Le Tourneau C; Cassier PA; Toulmonde M; D'Angelo SP; Campone M; Weber KL; Loirat D; Cannarile MA; Jegg AM; Ries C; Christen R; Meneses-Lorente G; Jacob W; Klaman I; Ooi CH; Watson C; Wonde K; Reis B; Michielin F; Rüttinger D; Delord JP; Blay JY
    Ann Oncol; 2019 Aug; 30(8):1381-1392. PubMed ID: 31114846
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Population pharmacokinetic characteristics of cemiplimab in patients with advanced malignancies.
    Yang F; Paccaly AJ; Rippley RK; Davis JD; DiCioccio AT
    J Pharmacokinet Pharmacodyn; 2021 Aug; 48(4):479-494. PubMed ID: 33728546
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
    Friedlander M; Meniawy T; Markman B; Mileshkin L; Harnett P; Millward M; Lundy J; Freimund A; Norris C; Mu S; Wu J; Paton V; Gao B
    Lancet Oncol; 2019 Sep; 20(9):1306-1315. PubMed ID: 31378459
    [TBL] [Abstract][Full Text] [Related]  

  • 11. First-in-human phase I/Ib open-label dose-escalation study of GWN323 (anti-GITR) as a single agent and in combination with spartalizumab (anti-PD-1) in patients with advanced solid tumors and lymphomas.
    Piha-Paul SA; Geva R; Tan TJ; Lim DW; Hierro C; Doi T; Rahma O; Lesokhin A; Luke JJ; Otero J; Nardi L; Singh A; Xyrafas A; Chen X; Mataraza J; Bedard PL
    J Immunother Cancer; 2021 Aug; 9(8):. PubMed ID: 34389618
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase I Study Evaluating WEE1 Inhibitor AZD1775 As Monotherapy and in Combination With Gemcitabine, Cisplatin, or Carboplatin in Patients With Advanced Solid Tumors.
    Leijen S; van Geel RM; Pavlick AC; Tibes R; Rosen L; Razak AR; Lam R; Demuth T; Rose S; Lee MA; Freshwater T; Shumway S; Liang LW; Oza AM; Schellens JH; Shapiro GI
    J Clin Oncol; 2016 Dec; 34(36):4371-4380. PubMed ID: 27601554
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Safety, antitumor activity, and pharmacokinetics of dostarlimab, an anti-PD-1, in patients with advanced solid tumors: a dose-escalation phase 1 trial.
    Patnaik A; Weiss GJ; Rasco DW; Blaydorn L; Mirabella A; Beeram M; Guo W; Lu S; Danaee H; McEachern K; Im E; Sachdev JC
    Cancer Chemother Pharmacol; 2022 Jan; 89(1):93-103. PubMed ID: 34750637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A phase I dose-escalation study of MEDI-575, a PDGFRα monoclonal antibody, in adults with advanced solid tumors.
    Becerra CR; Conkling P; Vogelzang N; Wu H; Hong S; Narwal R; Liang M; Tavakkoli F; Pandya N
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):917-25. PubMed ID: 25149088
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase I dose-escalation study of cabazitaxel administered in combination with cisplatin in patients with advanced solid tumors.
    Lockhart AC; Sundaram S; Sarantopoulos J; Mita MM; Wang-Gillam A; Moseley JL; Barber SL; Lane AR; Wack C; Kassalow L; Dedieu JF; Mita AC
    Invest New Drugs; 2014 Dec; 32(6):1236-45. PubMed ID: 25117475
    [TBL] [Abstract][Full Text] [Related]  

  • 16. First-In-Human Study of Cemiplimab Alone or In Combination with Radiotherapy and/or Low-dose Cyclophosphamide in Patients with Advanced Malignancies.
    Papadopoulos KP; Johnson ML; Lockhart AC; Moore K; Falchook GS; Formenti SC; Naing A; Carvajal RD; Rosen LS; Weiss GJ; Leidner RS; Li J; Paccaly A; Feng M; Stankevich E; Lowy I; Fury MG; Crittenden MR
    Clin Cancer Res; 2020 Mar; 26(5):1025-1033. PubMed ID: 31796520
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase 1a/1b trial of CSF-1R inhibitor LY3022855 in combination with durvalumab or tremelimumab in patients with advanced solid tumors.
    Falchook GS; Peeters M; Rottey S; Dirix LY; Obermannova R; Cohen JE; Perets R; Frommer RS; Bauer TM; Wang JS; Carvajal RD; Sabari J; Chapman S; Zhang W; Calderon B; Peterson DA
    Invest New Drugs; 2021 Oct; 39(5):1284-1297. PubMed ID: 33852104
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-TIGIT Antibody Tiragolumab Alone or With Atezolizumab in Patients With Advanced Solid Tumors: A Phase 1a/1b Nonrandomized Controlled Trial.
    Kim TW; Bedard PL; LoRusso P; Gordon MS; Bendell J; Oh DY; Ahn MJ; Garralda E; D'Angelo SP; Desai J; Hodi FS; Wainberg Z; Delord JP; Cassier PA; Cervantes A; Gil-Martin M; Wu B; Patil NS; Jin Y; Hoang T; Mendus D; Wen X; Meng R; Cho BC
    JAMA Oncol; 2023 Nov; 9(11):1574-1582. PubMed ID: 37768658
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I dose-escalation study of LY2875358, a bivalent MET antibody, given as monotherapy or in combination with erlotinib or gefitinib in Japanese patients with advanced malignancies.
    Yoh K; Doi T; Ohmatsu H; Kojima T; Takahashi H; Zenke Y; Wacheck V; Enatsu S; Nakamura T; Turner K; Uenaka K
    Invest New Drugs; 2016 Oct; 34(5):584-95. PubMed ID: 27422720
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Dose exploration results from Phase 1 study of cemiplimab, a human monoclonal programmed death (PD)-1 antibody, in Japanese patients with advanced malignancies.
    Kitano S; Shimizu T; Koyama T; Ebata T; Iwasa S; Kondo S; Shimomura A; Fujiwara Y; Yamamoto N; Paccaly A; Li S; Rietschel P; Sims T
    Cancer Chemother Pharmacol; 2021 Jan; 87(1):53-64. PubMed ID: 33146741
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.